Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02598557

Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer

Stage IIB Breast Cancer AJCC v6 and v7 Clinical Trial

Official title:
Alternative Dosing of Exemestane in Postmenopausal Women With Stage 0-II ER-Positive Breast Cancer: A Randomized Presurgical Trial

Clinical Trial Summary

This phase IIb trial studies how well alternative dosing of exemestane before surgery works in treating in postmenopausal patients with stage 0-II estrogen positive breast cancer. Chemoprevention is the use of drugs to keep breast cancer from forming or coming back. The use of exemestane may treat early stage (stage 0-II) breast cancer. Comparing the exemestane standard dose regimen versus two alternative, less frequent dose regimens may decrease undesirable symptoms and have similar efficacy in reducing serum estradiol.

Clinical Trial Description

We have conducted an international, multicenter, pre-surgical double-blind non-inferiority phase IIb study in which a total of 180 participants have been randomized to receive either exemestane 25 mg/day (Exemestane 25 mg QD) or 25 mg/ three times a week (Exemestane 25 mg TIW) or a single dose of 25 mg/week (Exemestane 25 mg QW) for a minimum of 4 up to 6 weeks. Participants were stratified by center and BMI (<25 kg/m2 vs >25 kg/m2). Participants were histologically confirmed ER-positive (ER >10%) primary breast cancer patients who were candidates for breast surgery. Postmenopausal women younger than 76 years of age with cT0-2, cN0-1, Mx or women with larger tumors who refuse neo-adjuvant therapy before surgery were eligible. No previous treatment for breast cancer was allowed. Complete physical exam and safety lab tests have been performed at baseline and at the end of treatment (28+1, 35+1, 42+1 days). Phone contact occurred on day 1 and a week before surgery (+3 days). Participants experiencing persistent adverse events (certainly, probably, and possibly treatment-related) have been monitored 20-30 days after study completion. Biomarkers: blood samples were collected at baseline and the end of treatment (fasting blood for biomarkers collected prior to randomization and either on the day of surgery or the day before; fasting strongly recommended but not mandated), tissue samples collected from the diagnostic or research biopsy and at the time of surgery. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02598557
Study type Interventional
Source National Cancer Institute (NCI)
Contact
Status Completed
Phase Phase 2
Start date December 6, 2016
Completion date February 2, 2023
View Details
See also
  Status Clinical Trial Phase
Completed NCT02689427 - Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer Phase 2
Active, not recruiting NCT02754752 - Electroacupuncture Therapy in Reducing Chronic Pain in Patients After Breast Cancer Treatment Phase 2
Completed NCT03094052 - Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib Phase 2
Active, not recruiting NCT03317405 - Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery Phase 1
Recruiting NCT02276443 - Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative N/A
Active, not recruiting NCT01245712 - Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer Phase 2
Completed NCT00005970 - Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer Phase 3
Active, not recruiting NCT00861705 - Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery Phase 2
Recruiting NCT03391453 - Proton Beam Radiation Therapy in Treating Patients With Breast Cancer After Surgery Phase 2
Completed NCT03454529 - The Effect of Simvastatin on Breast Cancer Cell Growth in Women With Stage I-II Breast Cancer Phase 2
Active, not recruiting NCT03077841 - Hypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast Cancer Phase 2/Phase 3
Active, not recruiting NCT03012100 - Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer Phase 2
Completed NCT03407716 - Ginseng in Decreasing Cancer-Related Fatigue After Treatment in Cancer Survivors Early Phase 1
Active, not recruiting NCT02079662 - The Role of Lifestyle Factors in Breast Cancer-Related Outcomes N/A
Active, not recruiting NCT04054557 - Patient Reported Outcomes, Smart Pill Bottle and Teleheath for Endocrine Therapy Adherence N/A
Completed NCT03568526 - Sensorimotor Rehabilitation Program in Improving Quality of Life in Patients With Early Stage Breast Cancer N/A
Completed NCT03319342 - Kindness Interventions in Enhancing Well-Being in Breast Cancer Survivors N/A
Active, not recruiting NCT01275677 - Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Phase 3
Recruiting NCT02945579 - Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy N/A
Active, not recruiting NCT02003209 - Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer Phase 3